MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and other unlawful business practices, with investors urged to apply as Lead Plaintiff by May 26, 2026, to protect their interests.
- FDA Warning Letter: A warning letter from the FDA, made public on March 24, 2026, asserts that ImmunityBio continues to promote its bladder cancer drug Anktiva in a misleading manner despite prior warnings, which could severely impact the company's reputation.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price plummeted by 21.12% on March 24, 2026, dropping $1.99 to close at $7.41, reflecting market concerns over the company's compliance and future outlook.
- Law Firm's Reputation: Pomerantz LLP, a premier class action law firm with over 85 years of experience, specializes in securities fraud and corporate misconduct cases, having secured multimillion-dollar settlements for victims, highlighting its significant influence in the legal field.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (IBRX) for transactions between January 19 and March 24, 2026, with investors required to apply for lead plaintiff status by May 26, 2026, highlighting the firm's commitment to protecting investor rights.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which may mislead investors about the company's prospects and affect future financing and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's executives made inaccurate claims about Anktiva on a podcast, resulting in a 21.12% drop in stock price, directly causing financial losses for investors and reflecting significant compliance risks for the company.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact the firm for information on how to participate in the lawsuit, indicating the firm's proactive role in securities fraud cases aimed at providing legal support and potential financial recovery for investors.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara faces a class action from May 20, 2024, to January 9, 2026, alleging that manufacturing issues and clinical trial risks overstated its FDA approval prospects, potentially leading to significant negative impacts on its financial condition.
- Coty's Underperformance: Coty Inc. is involved in a class action from November 5, 2025, to February 4, 2026, claiming that its Consumer Beauty segment underperformed and increased marketing investments compressed margins, rendering the company's positive statements materially misleading.
- Super Micro Computer Compliance Issues: Super Micro Computer faces a class action from February 2, 2024, to March 19, 2026, due to server sales to Chinese companies violating U.S. export control laws, indicating material weaknesses in compliance controls that jeopardize business prospects.
- ImmunityBio's Overstated Capabilities: ImmunityBio is part of a class action from January 19, 2026, to March 24, 2026, alleging that executive claims about Anktiva's capabilities were materially misleading, which could undermine investor confidence in the company's operations.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva during a podcast, which resulted in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has launched a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the case.
- Efficacy Claims Controversy: Soon-Shiong's assertion that Anktiva can treat all cancers has been flagged by the FDA as misleading, stating that promotional materials fail to provide complete information regarding Anktiva's FDA-approved indications, raising significant public health concerns and increasing legal risks for the company.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and encourages whistleblowers to provide information to assist the investigation, while emphasizing the SEC Whistleblower program offers rewards of up to 30% for original information, aiming to protect investor rights.
See More
Faruqi & Faruqi Encourages ImmunityBio Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, emphasizing the importance of timely action.
- Investor Rights Protection: Through this investigation, Faruq & Faruqi aims to provide legal support for affected investors, ensuring they can effectively safeguard their rights in the face of potential losses, thereby enhancing investor confidence in the market.
See More
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and other unlawful business practices, with investors urged to apply as Lead Plaintiff by May 26, 2026, to protect their interests.
- FDA Warning Letter: A warning letter from the FDA, made public on March 24, 2026, asserts that ImmunityBio continues to promote its bladder cancer drug Anktiva in a misleading manner despite prior warnings, which could severely impact the company's reputation.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price plummeted by 21.12% on March 24, 2026, dropping $1.99 to close at $7.41, reflecting market concerns over the company's compliance and future outlook.
- Law Firm's Reputation: Pomerantz LLP, a premier class action law firm with over 85 years of experience, specializes in securities fraud and corporate misconduct cases, having secured multimillion-dollar settlements for victims, highlighting its significant influence in the legal field.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (IBRX) for transactions between January 19 and March 24, 2026, with investors required to apply for lead plaintiff status by May 26, 2026, highlighting the firm's commitment to protecting investor rights.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which may mislead investors about the company's prospects and affect future financing and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's executives made inaccurate claims about Anktiva on a podcast, resulting in a 21.12% drop in stock price, directly causing financial losses for investors and reflecting significant compliance risks for the company.
- Legal Consultation Opportunity: Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact the firm for information on how to participate in the lawsuit, indicating the firm's proactive role in securities fraud cases aimed at providing legal support and potential financial recovery for investors.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara faces a class action from May 20, 2024, to January 9, 2026, alleging that manufacturing issues and clinical trial risks overstated its FDA approval prospects, potentially leading to significant negative impacts on its financial condition.
- Coty's Underperformance: Coty Inc. is involved in a class action from November 5, 2025, to February 4, 2026, claiming that its Consumer Beauty segment underperformed and increased marketing investments compressed margins, rendering the company's positive statements materially misleading.
- Super Micro Computer Compliance Issues: Super Micro Computer faces a class action from February 2, 2024, to March 19, 2026, due to server sales to Chinese companies violating U.S. export control laws, indicating material weaknesses in compliance controls that jeopardize business prospects.
- ImmunityBio's Overstated Capabilities: ImmunityBio is part of a class action from January 19, 2026, to March 24, 2026, alleging that executive claims about Anktiva's capabilities were materially misleading, which could undermine investor confidence in the company's operations.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva during a podcast, which resulted in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has launched a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the case.
- Efficacy Claims Controversy: Soon-Shiong's assertion that Anktiva can treat all cancers has been flagged by the FDA as misleading, stating that promotional materials fail to provide complete information regarding Anktiva's FDA-approved indications, raising significant public health concerns and increasing legal risks for the company.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and encourages whistleblowers to provide information to assist the investigation, while emphasizing the SEC Whistleblower program offers rewards of up to 30% for original information, aiming to protect investor rights.
See More
Faruqi & Faruqi Encourages ImmunityBio Investors to Reach Out
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, emphasizing the importance of timely action.
- Investor Rights Protection: Through this investigation, Faruq & Faruqi aims to provide legal support for affected investors, ensuring they can effectively safeguard their rights in the face of potential losses, thereby enhancing investor confidence in the market.
See More
